In the realm of neurodegenerative disease research, Natural Killer (NK) cells are gaining attention for their potential role in conditions like Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. Although intriguing, current clinical evidence is still in its infancy, and NK cell therapy has yet to be established as a treatment for these ailments. Part of the body’s innate immune system, NK cells are tasked with identifying and eliminating infected or abnormal cells. They also engage with other immune cells to modulate inflammatory responses, making their study increasingly relevant in the context of neurodegeneration, where inflammation and abnormal protein accumulation play significant roles.
In a pioneering Phase I clinical trial conducted in 2025, researchers explored the effects of expanded NK cells on Alzheimer’s patients. This small-scale study involved 11 participants, 10 of whom completed the analysis, receiving autologous, non-genetically modified expanded NK cell infusions every three weeks. The primary aim was to evaluate safety, with additional monitoring of cognitive functions and cerebrospinal fluid biomarkers linked to neuroinflammation and neurodegeneration. While no adverse events were connected to the NK cell product, and preliminary changes in biomarkers like pTau181 and GFAP were noted, the study was not designed to determine the efficacy of NK cells in halting or reversing Alzheimer’s disease. Further extensive trials are needed to ascertain their potential clinical benefits.
Parkinson’s disease research has also highlighted NK cells, particularly following a 2020 study in the Proceedings of the National Academy of Sciences. This study demonstrated that NK cells could interact with and break down alpha-synuclein aggregates in lab and animal models. When NK cells were depleted in a mouse model, researchers noted increased alpha-synuclein pathology and neuroinflammation, suggesting that NK cells might regulate immune activities related to Parkinson’s disease. Despite these promising preclinical findings, the therapeutic potential of NK cells for treating Parkinson’s in humans remains unproven.
The complexity of NK cells’ roles in neurological disorders is becoming increasingly evident. Different populations of NK cells can have varied functions, influenced by disease type, stage, and the tissue environment. As such, merely increasing NK cell numbers may not yield beneficial outcomes. Research continues to focus on identifying which NK cell populations, activation statuses, doses, and treatment schedules might be therapeutically advantageous. Critical questions remain unanswered, such as the capability of infused NK cells to affect the central nervous system, their longevity, the patient populations that might benefit, and whether they can alter disease trajectories long-term.
While NK cells are recognized for their role in immune surveillance and regulation, the therapeutic application of NK cell therapy for neurodegenerative diseases remains largely unestablished. Current research suggests interactions with neuroinflammation and protein aggregates, particularly alpha-synuclein, yet tangible clinical benefits in humans are unconfirmed. Anyone considering cellular therapies should consult healthcare professionals to navigate the scientific evidence and safety information. As NK cell therapy for Alzheimer’s and Parkinson’s is still investigational, it should not be regarded as an established treatment.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.